A study in The Lancet Public Health found lead contamination accounts for 412,000 deaths each year in the US, including more than 250,000 from cardiovascular disease. The study found a 37% increase in mortality and a 70% increase in cardiovascular disease mortality among people with an initial blood lead concentration at the 90th percentile, compared with people at the 10th percentile.
An analysis of 6,814 patients who did not have cardiovascular disease symptoms at the start of the study showed 10-year health care costs associated with CVD were $23,142 per patient, with 78% of that linked to medication use, according to a study in the Journal of the American College of Cardiology. "Maintenance of a healthy population has the potential to markedly reduce the economic burden of CVD among asymptomatic individuals," researchers wrote.
The Great Recession from 2008 to 2010 was associated with significant increases in fasting glucose and blood pressure among US adults, especially among those who took medications before the recession, according to a study in the Proceedings of the National Academy of Sciences. Researchers analyzed data from the Multi-Ethnic Study of Atherosclerosis and found reductions in the intensity and prevalence of medication use after the recession.
Researchers analyzed data from the CANVAS Program involving 10,142 patients with type 2 diabetes and a history of cardiovascular disease or high CVD risk and found that the SGLT2 inhibitor canagliflozin was associated with a 22% reduced risk of CV death or hospitalization for heart failure. The findings, presented at the American College of Cardiology meeting and published in Circulation, revealed that canagliflozin reduced the risks of CVD or heart failure deaths resulting in hospital admission by 39% among those with a history of heart failure, compared with a 13% reduced risk among patients without heart problems.
Researchers evaluated data from the REGARDS study involving 7,216 participants and found that among those who discontinued statin therapy, 25.4% with diabetes but without cardiovascular disease, 31.8% with a 10-year CVD risk less than 7.5%, 27.6% with a CVD history and 34.8% at high risk for CVD said they discontinued statins because they didn't think they were needed. The findings, presented at the American College of Cardiology meeting, revealed that more than half of the patients from each group did not want to reinitiate treatment.
Lower hypertension guidelines issued last year are meant to get people to make lifestyle changes that lower their blood pressure and reduce their cardiovascular risk, said PCNA Fellow Cheryl Dennison Himmelfarb of the Johns Hopkins University School of Nursing. Himmelfarb said the purpose is not to frighten people but to ensure they know their blood pressure values and goals, their cardiovascular risks and their options for reducing blood pressure so they can have longer, healthier lives.
Can't make the trip to Baltimore? Enjoy high-quality speakers and cutting-edge content from the comfort of your home or office. With the Cardiovascular Nursing Symposium webcast, you have the option to watch the meeting as it happens or view the recording for three months afterward. Either way, you'll be earning 14.5 CE contact hours while learning the latest in CVD prevention and management ... and no one will see you in your slippers. Learn more.
Innovative medicines can have significant impacts on individuals who would otherwise have sub-optimal management of their condition, but the path to acquiring these medicines can be difficult. Our new article highlights some of the barriers that both patients and providers face with the prior authorization process and how to overcome these challenges. Read the article.